Madam Chair, I thank the member for explaining so deftly the ins and outs of regulatory processes in Canada, including the changes we have made to accelerate access to medications and medical devices, particularly during the pandemic. It is a testimony to Canadian integrity that our regulators are seen worldwide as leaders in this field.
In response to borders, the member is right. Since the pandemic, we have taken successively stronger measures at the borders, first, going from screening from affected countries, and then later to actually restricting entry for non-essential travellers and foreign nationals.
Obviously Canadians always have the right to come home, as the member has pointed out. Even for Canadians returning home, we have additional measures, including mandatory quarantines for 14 days. We even have quarantine facilities for people who are coming into Canada who are either ill or unable to quarantine safely, to ensure that we can catch any importations of illness.
A lot has happened on the border. As the member points out, some Canadians are frustrated, on the other side, about the border measures and how it either restricts travel or it restricts reunification with friends and extended family.
There is a lot of work happening right now to better understand how to manage the border to prevent importation, but also to do so in a way that allows for increased mobility. It is very exciting to have ongoing border pilot projects doing that work of gathering research right now, including one in partnership with the Province of Alberta. These testing—